Abstract | BACKGROUND:
Edoxaban is a novel, potent and orally active direct Factor Xa (FXa) inhibitor under development for prophylaxis and treatment of thromboembolic diseases. Properties of dose response and margin of safety of anticoagulants are the key factors for a positive risk/benefit of novel oral anticoagulants. OBJECTIVES: METHODS: RESULTS: CONCLUSIONS: These results suggest that edoxaban may be more easily controlled and has the potential for a more positive risk/benefit ratio compared to conventional anticoagulants.
|
Authors | Yoshiyuki Morishima, Yuko Honda, Chikako Kamisato, Toshiro Shibano |
Journal | Thrombosis research
(Thromb Res)
Vol. 132
Issue 2
Pg. 234-9
(Aug 2013)
ISSN: 1879-2472 [Electronic] United States |
PMID | 23768448
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Hirudins
- Pyridines
- Recombinant Proteins
- Thiazoles
- Warfarin
- Heparin
- edoxaban
- lepirudin
|
Topics |
- Animals
- Anticoagulants
(pharmacology)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Factor Xa Inhibitors
- Heparin
(pharmacology)
- Hirudins
(pharmacology)
- Male
- Pyridines
(pharmacology)
- Rats
- Rats, Wistar
- Recombinant Proteins
(pharmacology)
- Thiazoles
(pharmacology)
- Thromboembolism
(drug therapy)
- Warfarin
(pharmacology)
|